Clinical Trials Logo

Clinical Trial Summary

The primary objectives of this study are to evaluate the efficacy of DTX401 to reduce or eliminate dependence on exogenous glucose replacement therapy to maintain euglycemia and to maintain or improve the quality of glucose control.


Clinical Trial Description

Study DTX401-CL301 is a phase 3 study to determine the efficacy and confirm the safety of DTX401 in patients 8 years and older with glycogen storage disease type Ia (GSDIa). Participants will be randomized 1:1 to DTX401 or placebo group, and followed closely for 48 weeks. At week 48 eligible participants will cross over and receive DTX401 if they had previously received placebo or placebo if they had previously received DTX401, and will be followed closely for an additional 96 weeks. After completion of week 144 or early withdrawal, participants will be offered enrollment into a Disease Monitoring Program (DMP) where they will be followed for at least 10 years post DTX401 infusion. In Japan, there will be a single open label study arm and all participants will be treated with DTX401. At week 48, Japanese participants will be offered enrollment into a Disease Monitoring Program (DMP) where they will be followed for at least 10 years post DTX401 infusion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05139316
Study type Interventional
Source Ultragenyx Pharmaceutical Inc
Contact
Status Active, not recruiting
Phase Phase 3
Start date November 8, 2021
Completion date February 2026

See also
  Status Clinical Trial Phase
Completed NCT04708015 - Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa
Completed NCT01854242 - Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
Completed NCT02054832 - Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard Versus Modified Uncooked Cornstarch N/A
Terminated NCT04909346 - Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
Active, not recruiting NCT03970278 - Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia
Completed NCT04311307 - Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Phase 1/Phase 2